Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
825 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04753658 | Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | terminated | — | 15 | PfizerINDUSTRY | 6 | Sep 23, 2024 | clinicaltrials |
| NCT03280303 | Palbociclib in Real World Practice | completed | — | 1,285 | PfizerINDUSTRY | 2 | Sep 20, 2024 | clinicaltrials |
| NCT04351334 |
| Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns |
| completed |
| — |
| 161 |
| PfizerINDUSTRY |
| 1 |
| Sep 19, 2024 |
| clinicaltrials |
| NCT04375150 | Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | completed | — | 355 | PfizerINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00151476 | Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients | terminated | — | 68 | PfizerINDUSTRY | 4 | Sep 4, 2024 | clinicaltrials |
| NCT03284723 | PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors | terminated | Phase 1 | 95 | PfizerINDUSTRY | 6 | Sep 3, 2024 | clinicaltrials |
| NCT03674827 | Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | terminated | Phase 1 | 36 | PfizerINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04176354 | Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy | completed | — | 813 | PfizerINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03343054 | A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 28 | PfizerINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT05462639 | Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma(MAGNETISMM17) | no longer available | — | — | PfizerINDUSTRY | 2 | Aug 9, 2024 | clinicaltrials |
| NCT02554812 | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | terminated | Phase 1 / Phase 2 | 409 | PfizerINDUSTRY | 8 | Jul 30, 2024 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT05770713 | A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer. | completed | — | 48 | PfizerINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT04669366 | Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries | completed | — | 1,205 | PfizerINDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT02473497 | Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients | no longer available | — | — | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03726333 | Hepatic Impairment Study for Lorlatinib in Cancer Patients | terminated | Phase 1 | 1 | PfizerINDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05361655 | Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor | completed | — | 2,888 | PfizerINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT05565391 | A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | completed | — | 508 | PfizerINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT02663518 | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | terminated | Phase 1 | 249 | PfizerINDUSTRY | 2 | May 10, 2024 | clinicaltrials |
| NCT03140176 | Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.(OPTIMISE) | terminated | — | 77 | PfizerINDUSTRY | 4 | May 10, 2024 | clinicaltrials |
| NCT00953758 | A Study Of PF-04449913 In Select Hematologic Malignancies | completed | Phase 1 | 47 | PfizerINDUSTRY | 2 | Apr 25, 2024 | clinicaltrials |
| NCT05699135 | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer | terminated | — | 150 | PfizerINDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT00728390 | A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks | completed | Phase 1 | 74 | PfizerINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
| NCT00942968 | Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer | completed | Phase 4 | 338 | PfizerINDUSTRY | 5 | Apr 18, 2024 | clinicaltrials |
| NCT04721821 | Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy. | completed | — | 7,807 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03472560 | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | terminated | Phase 2 | 61 | PfizerINDUSTRY | 8 | Apr 9, 2024 | clinicaltrials |
| NCT03148795 | A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 128 | PfizerINDUSTRY | 14 | Apr 5, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04979988 | Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients | completed | — | 51 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT01942135 | Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | completed | Phase 3 | 521 | PfizerINDUSTRY | 17 | Apr 4, 2024 | clinicaltrials |
| NCT02603432 | A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) | completed | Phase 3 | 700 | PfizerINDUSTRY | 29 | Mar 27, 2024 | clinicaltrials |
| NCT01543698 | A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 189 | PfizerINDUSTRY | 9 | Mar 13, 2024 | clinicaltrials |
| NCT02156895 | Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea | completed | — | 111 | PfizerINDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT01286467 | A Study Of PF-04449913 Administered Alone In Select Solid Tumors | completed | Phase 1 | 23 | PfizerINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT02159066 | LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma(LOGIC-2) | completed | Phase 2 | 158 | PfizerINDUSTRY | 9 | Mar 5, 2024 | clinicaltrials |
| NCT02140736 | Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology(ORHEO) | completed | — | 2,333 | Hospira, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05141708 | Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m | completed | — | 33 | PfizerINDUSTRY | 1 | Feb 16, 2024 | clinicaltrials |
| NCT01320085 | A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma | completed | Phase 2 | 183 | PfizerINDUSTRY | 5 | Jan 24, 2024 | clinicaltrials |
| NCT04987931 | Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer | completed | — | 84 | PfizerINDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT02367456 | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients(BRIGHT 1012) | completed | Phase 1 | 73 | PfizerINDUSTRY | 6 | Jan 19, 2024 | clinicaltrials |
| NCT04803305 | Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia | completed | Phase 1 | 18 | PfizerINDUSTRY | 2 | Jan 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials